【Metagen Therapeutics, Inc.】 New Insights into Fecal Microbiota Transplantation for Ulcerative Colitis: Identifying “Optimal Donor Profiles” and the Importance of Donor–Recipient Matching — Toward the establishment of microbiome-based therapeutics —

2025.05.01

A research group led by Dr. Dai Ishikawa, Director of the Center for Microbiota Research at the Graduate School of Medicine, Juntendo University; Professor Akihito Nagahara of the Department of Gastroenterology, Juntendo University Faculty of Medicine; and Dr. Takuji Yamada, Chief Scientific Officer at Metagen Therapeutics, Inc., has revealed key factors influencing the efficacy of fecal microbiota transplantation (FMT), an emerging therapeutic approach for ulcerative colitis (UC).

The study identified the characteristics of “optimal donors” associated with improved treatment outcomes, as well as the importance of microbiome matching between donors and patients. These findings provide important insights toward the development and clinical application of microbiome-based therapies.

◆Click the link for more details
New Insights into Fecal Microbiota Transplantation for Ulcerative Colitis:
Identifying “Optimal Donor Profiles” and the Importance of Donor–Recipient Matching
— Toward the establishment of microbiome-based therapeutics —